<?xml version="1.0" encoding="UTF-8"?>
<p>ADS has enabled a range of medicinal chemistry strategies to be realised. It has enabled the discovery of ligands based on more constrained scaffolds (such as the AR modulators 
 <bold>1</bold>–
 <bold>3</bold>
 <xref rid="cmdc202000524-bib-0009" ref-type="ref">9</xref>); productive fragment growth (e. g., to give the AR agonists compounds 
 <bold>5</bold>–
 <bold>11</bold>
 <xref rid="cmdc202000524-bib-0011" ref-type="ref">11</xref>); expansion of compound series (e. g., the antibacterials 
 <bold>12</bold>–
 <bold>15</bold>
 <xref rid="cmdc202000524-bib-0012" ref-type="ref">12</xref>); and scaffold hopping (e. g., to give the p53/
 <italic>h</italic>DM2 inhibitors 
 <bold>17</bold>–
 <bold>20</bold>
 <xref rid="cmdc202000524-bib-0014" ref-type="ref">14</xref>). In each case, ADS enabled the parallel identification of distinctive starting points for bioactive molecular discovery.
</p>
